These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1280479)

  • 1. G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells.
    Anderson PM; Crist W; Hasz D; Carroll AJ; Myers DE; Uckun FM
    Blood; 1992 Dec; 80(11):2826-34. PubMed ID: 1280479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
    Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
    Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
    Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
    Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
    Haagen IA; van de Griend R; Clark M; Geerars A; Bast B; de Gast B
    Clin Exp Immunol; 1992 Dec; 90(3):368-75. PubMed ID: 1281055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
    Haagen IA; Geerars AJ; de Lau WB; Clark MR; van de Griend RJ; Bast BJ; de Gast BC
    Blood; 1994 Jul; 84(2):556-63. PubMed ID: 7517719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
    Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
    Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
    Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
    Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.
    Uckun FM; Jaszcz W; Ambrus JL; Fauci AS; Gajl-Peczalska K; Song CW; Wick MR; Myers DE; Waddick K; Ledbetter JA
    Blood; 1988 Jan; 71(1):13-29. PubMed ID: 3257143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.
    Haagen IA; de Lau WB; Bast BJ; Geerars AJ; Clark MR; de Gast BC
    Cancer Immunol Immunother; 1994 Dec; 39(6):391-6. PubMed ID: 7528094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
    Csóka M; Strauss G; Debatin KM; Moldenhauer G
    Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow.
    Manzke O; Berthold F; Huebel K; Tesch H; Diehl V; Bohlen H
    Int J Cancer; 1999 Mar; 80(5):715-22. PubMed ID: 10048973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
    Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
    Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
    Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
    Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
    J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells.
    Kaneko T; Fusauchi Y; Kakui Y; Masuda M; Akahoshi M; Teramura M; Motoji T; Okumura K; Mizoguchi H; Oshimi K
    Blood; 1993 Mar; 81(5):1333-41. PubMed ID: 8095165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
    Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
    J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A; Stevenson GT; Glennie MJ
    J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues.
    Uckun FM; Muraguchi A; Ledbetter JA; Kishimoto T; O'Brien RT; Roloff JS; Gajl-Peczalska K; Provisor A; Koller B
    Blood; 1989 Mar; 73(4):1000-15. PubMed ID: 2784064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.
    Uckun FM; Haissig S; Ledbetter JA; Fidler P; Myers DE; Kuebelbeck V; Weisdorf D; Gajl-Peczalska K; Kersey JH; Ramsay NK
    Blood; 1992 Jun; 79(12):3369-79. PubMed ID: 1375851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.